Table 3.
Probe ID no.‡ | Gene symbol‡ | p§ | Controls | Fold change† | ||
---|---|---|---|---|---|---|
Patients with persistent oligoarticular JIA | Patients with RF-negative polyarticular JIA | Patients with systemic JIA | ||||
1558662_s_at | BANK1 | 0.003 | 1.17 | 1.74 | 1.71 | 2.24 |
222891_s_at | BCL11A | 0.004 | 1.18 | 1.43 | 1.24 | 1.73 |
1553369_at | BCNP1 | 0.009 | 1.13 | 1.97 | 1.67 | 2.39 |
207655_s_at | BLNK | 0.005 | 1.23 | 1.65 | 1.59 | 2.1 |
1554343_a_at | BRDG1 | 0.01 | 1.18 | 1.68 | 1.61 | 2.28 |
236226_at | BTLA | 0.04 | 1.03 | 1.62 | 1.6 | 1.52 |
206398_s_at | CD19 | 0.004 | 1.21 | 2.16 | 2.07 | 2.75 |
204581_at | CD22 | 0.008 | 1.07 | 1.83 | 1.53 | 2.05 |
205692_s_at | CD38 | 0.003 | 1.5 | 1.61 | 1.48 | 1.44 |
215346_at | CD40 | 0.03 | 1.13 | 1.38 | 1.22 | 1.46 |
215925_s_at | CD72 | 0.03 | 1.17 | 2.01 | 2.23 | 3.14 |
205049_s_at | CD79A | 0.04 | 1.24 | 1.62 | 1.56 | 2.23 |
205297_s_at | CD79B | 0.03 | 1.25 | 1.62 | 1.59 | 1.95 |
209583_s_at | CD200 | 0.04 | 1 | 1.74 | 1.5 | 1.71 |
232204_at | EBF | 0.008 | 1.15 | 1.81 | 1.4 | 1.86 |
201025_at | EIF5B | 0.02 | 0.97 | 1.2 | 1.1 | 0.97 |
209762_x_at | SP110 | 0.03 | 1.17 | 1.24 | 1.1 | 1.19 |
210776_x_at | TCF3 | 0.003 | 1.02 | 1.17 | 1.14 | 1.08 |
See Table 1 for definitions.
Ratio of geometric mean of expression in patients with early-onset disease:geometric mean of expression in patients with late-onset disease, or ratio of geometric mean of expression in younger controls (age <6 years at time of sampling):geometric mean of expression in older controls (age ≥ 6 years at time of sampling).
Ratio of geometric mean of expression in patients with early-onset disease:geometric mean of expression in patients with late-onset disease, or ratio of geometric mean of expression in younger controls (age <6 years at time of sampling):geometric mean of expression in older controls (age ≥ 6 years at time of sampling).
Affymetrix HG-U133 Plus 2.0 GeneChips probe set ID numbers and gene symbols.
By false discovery rate adjusted t-test comparing samples from patients with early- and late-onset oligoarticular disease.